NIMODIPINE

Post-LOESM

nimodipine

R-Pharm US

ANDAORALSOLUTION

Approved

Jul 2024

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

3/8 — Basic

NIMODIPINE (nimodipine) by R-Pharm US is calcium channel antagonists [moa]. First approved in 2024.

Drug data last refreshed 18h ago

Mechanism of Action

Calcium Channel Antagonists

Pharmacologic Class:

Dihydropyridine Calcium Channel Blocker

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (2)

NCT06007573N/ACompleted

Acupuncture Combined With Nimodipine for Prevention of Post-stroke Dementia

Started Feb 2021

NCT00000738Phase 1Completed

Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1

36 enrolled

AIDS Dementia ComplexHIV Infections

Company

Worked on NIMODIPINE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.